<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=31313"><dc:title>European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy Author links open overlay panel</dc:title><dc:creator>Lula,	Lukadi Joseph	(Avtor)
	</dc:creator><dc:creator>Costa,	Rita	(Avtor)
	</dc:creator><dc:creator>Huang,	Lin	(Avtor)
	</dc:creator><dc:creator>Rushwan,	Amr	(Avtor)
	</dc:creator><dc:creator>Domjan,	Matic	(Avtor)
	</dc:creator><dc:creator>Franssen,	A.J.P.M.	(Avtor)
	</dc:creator><dc:creator>Weedle,	Rebecca	(Avtor)
	</dc:creator><dc:creator>Trabalza Marinucci,	Beatrice	(Avtor)
	</dc:creator><dc:creator>Forcada Barreda,	Clara	(Avtor)
	</dc:creator><dc:creator>Jašovič,	Črt	(Avtor)
	</dc:creator><dc:creator>Štupnik,	Tomaž	(Avtor)
	</dc:creator><dc:subject>segmentectomy</dc:subject><dc:subject>cancer</dc:subject><dc:subject>early-stage</dc:subject><dc:subject>non-small lung</dc:subject><dc:subject>canceroutcome</dc:subject><dc:description>Objectives To assess the impact of lung resection extent on early-stage non-small cell lung cancer with a history of any cancer. Methods Retrospective multicentric cohort study including patients with ≤2 cm pathologic size lung cancer with a history of any cancer, operated on from 2015 to 2021 across nine European centers (one per country). Overall survival (OS), disease-free survival (DFS) and lung cancer specific death (LCSD) between both groups were assessed before and after propensity score (PS) −matching. Risk factors for oncologic outcomes were analyzed using parsimonious model cox proportional hazard regression. Kaplan Meier and cumulative incidence function assessed the outcomes. Log-rank test and Gray’ test compared the groups. Linearized risk was used to assess recurrences. Results Of the 1910 patients with early-stage lung cancer patients, 540 (28.2%) had a prior cancer. Lobectomy and segmentectomy were performed in 409 (75.7%) and 131 (24.3%) patients respectively. 5-year OS rates: lobectomy 81.5%, segmentectomy 80.8%, p = 0.8; DFS: lobectomy 76.9%, segmentectomy 74.4%, p = 0.6 and LCSD: lobectomy 8.0%, segmentectomy 4.9%, p = 0.2. These finding were similar in the matched cohort. Locoregional recurrence (linearized risk: lobectomy 0.111, segmentectomy 0.066) and distant recurrence (linearized risk: lobectomy 0.093, segmentectomy 0.055) were not worse in the segmentectomy group. In multivariable analysis, prior cancer negatively impacted only lung cancer specific death HR:1.27 (95%CI:1.00–1.60). Conclusion Compared to lobectomy, segmentectomy has not shown a worse oncologic outcome in patients with history of any prior cancer.</dc:description><dc:date>2026</dc:date><dc:date>2026-07-27 12:51:22</dc:date><dc:type>Neznano</dc:type><dc:identifier>31313</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
